|
| 297例重组人促红素及铁剂治疗血液透析肾性贫血的合理性评价 |
| Rationality Evaluation of Recombinant Human Erythropoietin and Iron in Treating of Renal Anemia in Hemodialysis |
| |
| DOI： |
| 中文关键词: 血液透析 肾性贫血 重组人促红素 铁剂 |
| 英文关键词:Hemodialysis Renal anemia Recombinant human erythropoietin Iron |
| 基金项目: |
|
| 摘要点击次数: 1212 |
| 全文下载次数: 936 |
| 中文摘要: |
| 摘 要 目的：调查分析血液透析肾性贫血治疗药物的使用情况，建立点评标准，为临床合理用药提供参考。方法：利用信息化系统抽取西安中心区院2014年6月～2016年6月诊断为血液透析肾性贫血的患者共297例。根据临床指南、专家共识及药品说明书建立点评标准，评价分析治疗药物重组人促红素及铁剂的用药合理性。结果：重组人促红素用药不合理率为29.29%(87/297)，主要表现为该用药而未用；铁剂用药不合理率为56.23%(167/297)，主要表现为未检测铁蛋白含量而给予补铁。结论：血液透析肾性贫血药物治疗不合理现象普遍存在，需加强其合理用药的监管力度，保障患者用药安全。 |
| 英文摘要: |
| ABSTRACT Objective:To analyze the use of drugs for the treatment of renal anemia in hemodialysis, and to establish a special evaluation standard to provide reference for clinical rational use of drugs. Methods: From June 2014 to June 2016, clinical data of 297 patients with renal anemia diagnosed by hemodialysis in hospital were collected by information management system. Based on the clinical guidelines, expert consensus and drug instruction to establish comment standard, evaluation the rational use of recombinant human erythropoietin (rhEPO) and iron. Results:Recombinant human erythropoietin using reasonable rate was 70.71%, iron using reasonable rate was 43.77%. The unreasonable rate of recombinant human erythropoietin was 29.29% (87/297), main problem was that the drug should be used but did not used. The unreasonable rate of iron was 56.23% (167/297), mainly showed that iron supplementation was not detected serum ferritin. Conclusion:The unreasonable treatment of renal anemia in hemodialysis patients was common, so it was necessary to strengthen the supervision of rational drug use and ensure the safety of patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
